A pharmacotherapeutic approach to the regulation of hyperinsulinemia and obesity.
A selective inhibitor of thromboxane synthase, Ro 22-3581 has been shown to be a useful tool for investigating the relationship between hyperinsulinemia and obesity. These studies have established that the pharmacologic normalization of the hyperinsulinemia associated with elevated weights in genetically obese and diet-induced obese rats resulted in decreased weight gain or weight loss. This effect was shown to be reversible, partially independent of the suppression of food intake, dependent on a functional endocrine pancreas, and not diabetogenic. However, these studies have not established a cause and effect relationship between the inhibition of thromboxane synthase activity by Ro 22-3581 and its suppression of insulin secretion and circulating insulin levels.
Triscari
J
J
Pharmacology and Chemotherapy, Hoffmann-La Roche Inc., Nutley, NJ 07110.
Sullivan
A C
AC
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood*; D009765:Obesity / Q000097:blood / Q000188:drug therapy*; D051381:Rats; D011924:Rats, Zucker; D013929:Thromboxane B2 / Q000097:blood; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*
D007093:Imidazoles; D007328:Insulin; C034480:Ro 22-3581; D013929:Thromboxane B2; D013930:Thromboxane-A Synthase